Advertisement
Advertisement
NTLA
Intellia Therapeutics, Inc
11.24
USDSponsored
+0.27
+2.46%
Aug 06, 15:59 UTC -4
Closed
After-Market
11.58
+0.34
+3.05%
NTLA Earnings Reports
Positive Surprise Ratio
NTLA beat 24 of 42 last estimates.
57%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$14.34M
/-$0.82
Implied change from Q2 26 (Revenue/ EPS)
+87.15%
/+2.50%
Implied change from Q3 25 (Revenue/ EPS)
+4.02%
/-10.87%
Intellia Therapeutics, Inc earnings per share and revenue
On Aug 06, 2026, NTLA reported earnings of -0.80 USD per share (EPS) for Q2 26, beating the estimate of -0.81 USD, resulting in a 1.86% surprise. Revenue reached 7.66 million, compared to an expected 14.18 million, with a -45.99% difference. The market reacted with a +2.46% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 13 analysts forecast an EPS of -0.82 USD, with revenue projected to reach 14.34 million USD, implying an increase of 2.50% EPS, and increase of 87.15% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Iovance Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.11
Surprise
+14.53%
Nuvation Bio Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.15
Surprise
+19.87%
Cullinan Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.82
Actual
-$0.81
Surprise
+1.94%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
Genmab A/S ADS
Report Date
Aug 06, 2026 For Q2 26
Estimate
$3.59
Actual
$0.54
Surprise
-84.98%
Scholar Rock Holding Corporation Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.85
Actual
-$0.84
Surprise
+2.01%
Immunovant, Inc. Common Stock
Report Date
Aug 06, 2026 For Q1 27
Estimate
-$0.62
Actual
-$0.75
Surprise
-19.48%
Zai Lab Limited - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.46
Surprise
-599.09%
FAQ
What were Intellia Therapeutics, Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Intellia Therapeutics, Inc reported EPS of -$0.80, beating estimates by 1.86%, and revenue of $7.66M, -45.99% below expectations.
How did the market react to Intellia Therapeutics, Inc's Q2 2026 earnings?
The stock price moved up 2.46%, changed from $10.97 before the earnings release to $11.24 the day after.
When is Intellia Therapeutics, Inc expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Intellia Therapeutics, Inc's next earnings report?
Based on 13
analysts, Intellia Therapeutics, Inc is expected to report EPS of -$0.82 and revenue of $14.34M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement